http://www.uk.sagepub.com/journalsProdDesc.nav?ct_p=manuscriptSubmission&prodId=Journal200775&crossRegion=asia
no more than 8000 words including the main text, references, endnotes and any appendices.
Friday, March 30, 2012
Wednesday, March 28, 2012
Projected Attorney Hires By Agency
http://www.ourpublicservice.org/OPS/publications/viewcontentdetails.php?id=118
Avue Central
https://www.avuedigitalservices.com/casting/aiportal/control/mainmenu;jsessionid=a13a53e530d5e80dd8c335174ff593bec3032e193d12.e38PaN8TbNaTaO0Mb3qSah0LaO0
Tuesday, March 27, 2012
How Can I Find Entry-Level Government Attorney Jobs?
http://www.law.gwu.edu/Careers/currentstudents/Documents/Graduating%20Students/Spg09How_to_Find_Entry_Level_Government_Attorney_Jobs.pdf
United States Government Manual
http://www.gpo.gov/fdsys/browse/collection.action?collectionCode=GOVMAN
Working on Capitol Hill
http://www.law.yale.edu/documents/pdf/CDO_Public/2010_PUBLIC_CAPITOL_HILL_GUIDE_FINAL.pdf
Position Classification Standard for General Attorney Series, GS-0905
http://www.opm.gov/fedclass/gs0905.pdf
Find Government Attorney Jobs: State and Federal Lawyer Jobs
http://www.howtodothings.com/careers/a2956-how-to-find-a-job-as-a-government-attorney.html
http://www.uchastings.edu/careers/docs/11.FederalGovernmentJobs.pdf
http://www.uchastings.edu/careers/docs/11.FederalGovernmentJobs.pdf
Eight Questions a Government Lawyer Should Ask Before Taking a Pro Bono Case
http://apps.americanbar.org/legalservices/probono/pl_zalenski.pdf
Monday, March 26, 2012
Government legal service, UK
http://www.gls.gov.uk/about/departments/gls-departments.htm
http://www.gls.gov.uk/lawyerrecruitment/Vacancy%20Files/GLS%20Information%20for%20candidates%20-%20Revised%20November%202011.pdf
http://www.gls.gov.uk/lawyerrecruitment/Vacancy%20Files/GLS%20Information%20for%20candidates%20-%20Revised%20November%202011.pdf
PHARNEXT raises an additional €8 million for its PleotherapyTM platform applied to the treatment of Charcot-Marie Tooth disease and Alzheimer's disease
http://www.pharnext.com/media/pdf/02072012_PR_Funding_Pharnext.pdf
http://www.pharnext.com/en/component/content/article/58-home/111-pharnext-news
After a €2.5-million round in June, this new funding takes the total raised in 2011 to €10.5 million Paris, February 9th 2012 - Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™
for severe neurological diseases, today announced that it had raised €8 million in
two rounds of fundraising in October and December 2011. This fundraising
activity follows the first €2.5-million round closed in June 2011.
The €8 million round of fundraising was performed in a private placement.
The round in June 2011 was performed with Parinvest (a company
controlled by Rallye, the holding company for the Casino supermarket group
(CEO: Jean-Charles Naouri)), La Financière Gaspard (managed by Georges
Sampeur, Chairman of the B&B Hotel Group) and Truffle Capital (a leading
European private equity firm managed by Philippe Pouletty MD, a Pharnext
co-founder).
"We thank our existing investors and new investors for their support. Thanks to
the success of the fundraising performed in 2011, we shall be able to ramp up
our breakthrough technology to target Alzheimer's disease1", commented
Pharnext co-founder and CEO Professor Daniel Cohen. "Charcot-Marie-Tooth
disease and Alzheimer's disease are severe neurodegenerative conditions that
lack satisfactory treatments; our unique PleotherapyTM 2 approach represents a
promising alternative for millions of patients worldwide".
These rounds of funding are intended to finance the further Phase II clinical
development of Pharnext's first Pleodrug™ in Charcot-Marie-Tooth disease type
1A 3 (for which Pharnext announced the completion of patient recruitment in
November 2011) and the ongoing development in Alzheimer's disease (notably
the start of clinical trials, scheduled for 2012).
Pharnext has a particularly solid funding structure:
- €3.5 million in seed funding with Truffle Capital (2007).
- an agreement with the pharmaceutical company Ipsen, worth up to €94 million
in lump sums and milestone payments (June 2009).
- €3.4 million in financial support from the OSEO innovation agency on Charcot-
Marie-Tooth disease (2007).
- a grant-in-aid from the French Muscular Dystrophy Association (AFM) in 2009.
- The DIPPAL project on diagnostic and therapeutic solutions for Alzheimer's
disease patients, funded by the OSEO's Strategic Industrial Innovation program
with a total of €10.4 million over 6 years to. Pharnext leads the DIPPAL
consortium and will receive €7.3 million (November 2010)
- €4.75 million raised in June 2010
- €2.5 million raised in June 2011
- €7.5 million raised in October 2011
- €0.5 million raised in December 2011
The Pharnext approach:
Pharnext focuses on meeting a range of medical needs, including diseases for
which there is no satisfactory treatment. This is achieved by moving from
conventional, single-drug therapy to Pleotherapy™. In fact, Pleotherapy™
involves a single, patented Pleodrug™ combining mini-doses of several off-patent
drugs already approved by the health authorities for the treatment of diseases
that are biologically but not clinically linked to the target indication. The company
has created a very sophisticated Pleotherapy™ R&D division and a powerful,
proprietary Pleodrug™ discovery engine based on “NEXUS”, a new, protected
process which is applicable to most diseases that makes it possible to efficiently
create Pleodrugs™ and new diagnostic or predictive tests.
http://www.pharnext.com/media/pdf/02072012_PR_Funding_Pharnext.pdf
http://www.pharnext.com/en/component/content/article/58-home/111-pharnext-news
After a €2.5-million round in June, this new funding takes the total raised in 2011 to €10.5 million Paris, February 9th 2012 - Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments based on Pleotherapy™
for severe neurological diseases, today announced that it had raised €8 million in
two rounds of fundraising in October and December 2011. This fundraising
activity follows the first €2.5-million round closed in June 2011.
The €8 million round of fundraising was performed in a private placement.
The round in June 2011 was performed with Parinvest (a company
controlled by Rallye, the holding company for the Casino supermarket group
(CEO: Jean-Charles Naouri)), La Financière Gaspard (managed by Georges
Sampeur, Chairman of the B&B Hotel Group) and Truffle Capital (a leading
European private equity firm managed by Philippe Pouletty MD, a Pharnext
co-founder).
"We thank our existing investors and new investors for their support. Thanks to
the success of the fundraising performed in 2011, we shall be able to ramp up
our breakthrough technology to target Alzheimer's disease1", commented
Pharnext co-founder and CEO Professor Daniel Cohen. "Charcot-Marie-Tooth
disease and Alzheimer's disease are severe neurodegenerative conditions that
lack satisfactory treatments; our unique PleotherapyTM 2 approach represents a
promising alternative for millions of patients worldwide".
These rounds of funding are intended to finance the further Phase II clinical
development of Pharnext's first Pleodrug™ in Charcot-Marie-Tooth disease type
1A 3 (for which Pharnext announced the completion of patient recruitment in
November 2011) and the ongoing development in Alzheimer's disease (notably
the start of clinical trials, scheduled for 2012).
Pharnext has a particularly solid funding structure:
- €3.5 million in seed funding with Truffle Capital (2007).
- an agreement with the pharmaceutical company Ipsen, worth up to €94 million
in lump sums and milestone payments (June 2009).
- €3.4 million in financial support from the OSEO innovation agency on Charcot-
Marie-Tooth disease (2007).
- a grant-in-aid from the French Muscular Dystrophy Association (AFM) in 2009.
- The DIPPAL project on diagnostic and therapeutic solutions for Alzheimer's
disease patients, funded by the OSEO's Strategic Industrial Innovation program
with a total of €10.4 million over 6 years to. Pharnext leads the DIPPAL
consortium and will receive €7.3 million (November 2010)
- €4.75 million raised in June 2010
- €2.5 million raised in June 2011
- €7.5 million raised in October 2011
- €0.5 million raised in December 2011
The Pharnext approach:
Pharnext focuses on meeting a range of medical needs, including diseases for
which there is no satisfactory treatment. This is achieved by moving from
conventional, single-drug therapy to Pleotherapy™. In fact, Pleotherapy™
involves a single, patented Pleodrug™ combining mini-doses of several off-patent
drugs already approved by the health authorities for the treatment of diseases
that are biologically but not clinically linked to the target indication. The company
has created a very sophisticated Pleotherapy™ R&D division and a powerful,
proprietary Pleodrug™ discovery engine based on “NEXUS”, a new, protected
process which is applicable to most diseases that makes it possible to efficiently
create Pleodrugs™ and new diagnostic or predictive tests.
Tuesday, March 13, 2012
Thought is the Response of Memory
What do we mean by thought? When do you think? Obviously, thought is the result of a response, neurological or psychological, the response of stored-up memory. There is the immediate response of the nerves to a sensation, and there is the psychological response of stored-up memory, the influence of race, group, guru, family, tradition, and so on - all of which you call thought. So, the thought process is the response of memory, is it not? You would have no thoughts if you had no memory, and the response of memory to a certain experience brings the thought process into action.
What Are You Doing with Your Life?
What Are You Doing with Your Life?
Thought Seeks Security
Thought is the very essence of security, and that is what the most bourgeois mind wants, security, security at every level! To bring about a total change of the human consciousness, thought must function at one level and must not function at another level. Thought must function naturally, normally at one level, the everyday level - physically, technologically, with knowledge, but must not overflow into another field where thought has no reality at all. If I had no thought I wouldn't be able to speak. But a radical change within myself as a human being cannot be brought about through thought, because thought can only function in relation to conflict. Thought can only breed conflict.
What Are You Doingwith Your Life?
What Are You Doingwith Your Life?
Why Change?
Man has lived for two million years or more, but he has not solved the problem of sorrow. He is always sorrow-ridden: he has sorrow as his shadow or as his companion. Sorrow of losing somebody; sorrow in not being able to fulfill his ambitions, his greed, his energy; sorrow of physical pain; sorrow of psychological anxiety; sorrow of guilt; sorrow of hope and despair - that has been the lot of man; that has been the lot of every human being. And he has always tried to solve this problem - to end sorrow within the field of consciousness, by trying to avoid it, by running away from sorrow, by suppressing it, by identifying himself with something greater than himself, by taking to drink, to women, by doing everything in order to avoid this anxiety, this pain, this despair, this immense loneliness and boredom of life - which is always within this field of consciousness, which is the result of time.
What Are You Doing with Your Life?
What Are You Doing with Your Life?
Loneliness: Living in the Prison of Me
There is the sorrow of loneliness. I do not know if you have ever been lonely: when you suddenly realize that you have no relationship with anybody. And this loneliness is a form of death. As we said, there is dying not only when life comes to an end but when there is no answer, there is no way out. That is also a form of death: being in the prison of your own self-centered activity, endlessly. When you are caught in your own thoughts, in your own agony, in your own superstitions, in your deadly, daily routine of habit and thoughtlessness, that is also death - not just the ending of the body. And how to end it also one must find out. The ending of sorrow is possible. What Are You Doing with Your Life?
Chinese Universities Send Big Signals to Foreigners
http://www.nytimes.com/2012/03/12/world/asia/12iht-educlede12.html
Thursday, March 08, 2012
Cost of Gene Sequencing Falls, Raising Hopes for Medical Advances
http://www.nytimes.com/2012/03/08/technology/cost-of-gene-sequencing-falls-raising-hopes-for-medical-advances.html
Wednesday, March 07, 2012
Cristina Garcia
online at www.cristinagarcia2012.com, and click the “Donate” button.
Oh, and here is some food for thought –a recent article from the LA Times that illustrates the kind of the things my opponent Tom Calderon has been up to: http://www.latimes.com/news/local/la-me-water-money-20120229,0,1557865.story
If you have any questions, please contact Arianne Garcia, she will be happy to help. Her number is 626-327-7295, and email: nuns23@gmail.com.
Oh, and here is some food for thought –a recent article from the LA Times that illustrates the kind of the things my opponent Tom Calderon has been up to: http://www.latimes.com/news/local/la-me-water-money-20120229,0,1557865.story
If you have any questions, please contact Arianne Garcia, she will be happy to help. Her number is 626-327-7295, and email: nuns23@gmail.com.
Tuesday, March 06, 2012
Monday, March 05, 2012
Goodness Has No Motive
Obviously, goodness has no motive because all motive is based on the self; it is the egocentric movement of the mind. So what do we mean by goodness? Surely, there is goodness only when there is total attention. Attention has no motive. When there is a motive for attention, is there attention? If I pay attention in order to acquire something, the acquisition, whether it be good or bad, is not attention, it is a distraction. A division. There can be goodness only when there is a totality of attention in which there is no effort to be or not to be. - J. Krishnamurti, The Book of Life
Human Evolution
Must we know drunkenness to know sobriety? Must you go through hate in order to know what it is to be compassionate? Must you go through wars, destroying yourself and others, to know what peace is? Surely, this is an utterly false way of thinking, is it not? First you assume that there is evolution, growth, a moving from bad to good, and then you fit your thinking into that pattern. Obviously, there is physical growth, the little plant becoming the big tree; there is technological progress, the wheel evolving through centuries into the jet plane. But is there psychological progress, evolution? That is what we are discussing, whether there is a growth, an evolution of the "me," beginning with evil and ending up in good. Through a process of evolution, through time, can the "me," which is the center of evil, ever become noble, good? Obviously not. That which is evil, the psychological "me," will always remain evil. But we do not want to face that. We think that through the process of time, through growth and change, the "I" will ultimately become reality. This is our hope, that is our longing - that the "I" will be made perfect through time. What is this "I," this "me"? It is a name, a form, a bundle of memories, hopes, frustrations, longings, pains, sorrows, passing joys. We want this "me" to continue and become perfect, and so we say that beyond the "me" there is a "super-me," a higher self, a spiritual entity which is timeless but since we have thought of it, that "spiritual" entity is still within the field of time, is it not? If we can think about it, it is obviously within the field of our reasoning. - J. Krishnamurti, The Book of Life
the i or the ideal me is conditioned within the field of my reasoning...
Sunday, March 04, 2012
Freedom from Occupation
Can the mind be free from the past, free from thought- not from the good or bad thought? How do I find out? I can only find out by seeing what the mind is occupied with. If my mind is occupied with the good or occupied with the bad, then it is only concerned with the past, it is occupied with the past. It is not free of the past. So, what is important is to find out how the mind is occupied. If it is occupied at all, it is always occupied with the past because all our consciousness is the past. The past is not only on the surface but on the highest level, and the stress on the unconscious is also the past. Can the mind be free from occupation? This means, can the mind be completely without being occupied and let memory, the thoughts good and bad, go by without choosing? The moment the mind is occupied with one thought, good or bad, then it is concerned with the past. If you really listen - not just merely verbally, but really profoundly - then you will see that there is stability that is not of the mind, which is the freedom from the past.Yet, the past can never be put aside. There is a watching of the past as it goes by, but not occupation with the past. So the mind is free to observe and not to choose. Where there is choice in this movement of the river of memory, there is occupation; and the moment the mind is occupied, it is caught in the past; and when the mind is occupied with the past, it is incapable of seeing something real, true, new, original, uncontaminated. - J. Krishnamurti, The Book of Life
Friday, March 02, 2012
behavioral scientist
- what are you doing now?
- why are you doing it?
- would my life be better or worse with or without this person?
Subscribe to:
Posts (Atom)
